Seelos Therapeutics Total Assets 2010-2022 | SEEL
Seelos Therapeutics total assets from 2010 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Seelos Therapeutics Annual Total Assets
(Millions of US $) |
| 2021 |
$84 |
| 2020 |
$17 |
| 2019 |
$11 |
| 2018 |
$0 |
| 2017 |
$7 |
| 2016 |
$5 |
| 2015 |
$8 |
| 2014 |
$15 |
| 2013 |
$23 |
| 2012 |
$24 |
| 2011 |
$17 |
| 2010 |
$19 |
| 2009 |
$21 |
Seelos Therapeutics Quarterly Total Assets
(Millions of US $) |
| 2022-09-30 |
$41 |
| 2022-06-30 |
$53 |
| 2022-03-31 |
$71 |
| 2021-12-31 |
$84 |
| 2021-09-30 |
$81 |
| 2021-06-30 |
$90 |
| 2021-03-31 |
$41 |
| 2020-12-31 |
$17 |
| 2020-09-30 |
$10 |
| 2020-06-30 |
$8 |
| 2020-03-31 |
$14 |
| 2019-12-31 |
$11 |
| 2019-09-30 |
$16 |
| 2019-06-30 |
$10 |
| 2019-03-31 |
$12 |
| 2018-12-31 |
$0 |
| 2018-09-30 |
$6 |
| 2018-06-30 |
$7 |
| 2018-03-31 |
$6 |
| 2017-12-31 |
$7 |
| 2017-09-30 |
$9 |
| 2017-06-30 |
$9 |
| 2017-03-31 |
$5 |
| 2016-12-31 |
$5 |
| 2016-09-30 |
$8 |
| 2016-06-30 |
$6 |
| 2016-03-31 |
$10 |
| 2015-12-31 |
$8 |
| 2015-09-30 |
$10 |
| 2015-06-30 |
$11 |
| 2015-03-31 |
$20 |
| 2014-12-31 |
$15 |
| 2014-09-30 |
$20 |
| 2014-06-30 |
$20 |
| 2014-03-31 |
$25 |
| 2013-12-31 |
$23 |
| 2013-09-30 |
$22 |
| 2013-06-30 |
$27 |
| 2013-03-31 |
$17 |
| 2012-12-31 |
$24 |
| 2012-09-30 |
$41 |
| 2012-06-30 |
$29 |
| 2012-03-31 |
$32 |
| 2011-12-31 |
$17 |
| 2011-09-30 |
$14 |
| 2011-06-30 |
$14 |
| 2011-03-31 |
$20 |
| 2010-12-31 |
$19 |
| 2010-09-30 |
$0 |
| 2010-06-30 |
$24 |
| 2010-03-31 |
$22 |
| 2009-12-31 |
$21 |
| 2009-09-30 |
$7 |
| 2009-06-30 |
$8 |
| 2009-03-31 |
$9 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.092B |
$0.000B |
|
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
|
